Phio Pharmaceuticals Corp. (PHIO) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.86 (-0.30% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHIO ranks #551 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $0 in revenue, -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.2 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PHIO currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.99) and Max Pain ($0.90) forces dealer call-delta covering toward $4.40.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Phio Pharmaceuticals Corp. (PHIO) slipped -0.30% to $0.86, trading at 2% of its 52-week range ($0.81 – $4.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceutica
View presentations from European and Canadian public growth companies following the October 7–8 eventNEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference s
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PHIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PHIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Phio Pharmaceuticals Corp. (PHIO) ranks #551 by composite RQD confidence (37/100, grade D-) and #891 by equity capitalization ($10.0M). Within this direct 5-issuer industry benchmark cohort, PHIO leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PHIO at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PHIO
ACTIVE
Phio Pharmaceuticals Corp. | D- | 37/100 | — | — | -35.0% | -0.30% | $10.0M | Benchmark Subject |
| CALC CalciMedica Inc. | D- | 38/100 | — | — | -35.0% | -16.57% | $10.0M | /calc-vs-phio → |
| TPST Tempest Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -7.07% | $9.9M | /tpst-vs-phio → |
| BLRX BioLineRx Ltd. | D | 46/100 | — | — | — | -1.48% | $9.9M | /blrx-vs-phio → |
| LTRN Lantern Pharma Inc. | E | 31/100 | — | — | -35.0% | -9.60% | $9.9M | /ltrn-vs-phio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Phio Pharmaceuticals Corp. (PHIO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.7M, operating cash flow of -$8.0M, and free cash flow of -$8.0M (-12.3% YoY). On the balance sheet, PHIO closed FY2025 with $21.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.7M | -$8.0M | -$8.0M | $21.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$7.2M | -$7.1M | -$7.1M | $5.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.8M | -$10.7M | -$10.7M | — | — |
As of 2026-11-03, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.86 (-0.30% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHIO ranks #551 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $0 in revenue, -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PHIO last traded at $0.86 (-0.30% on volume of 66,663 shares), positioning the stock -13.13% below its 50-day simple moving average ($0.99) and -21.10% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.81 to $4.19, PHIO sits at the 1.5% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($1.00 to $0.97).
Why PHIO Stock slipped -0.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PHIO scores 36 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the cash engine and the flow signals, which together indicate that the company is not currently generating cash returns and that institutional and insider signals are not supportive. The forensic pillar is the most balanced, with an Altman Z of 2.5 and a Debt/Equity of 0.5, but the Piotroski F-Score of 1 out of 9 signals weak financial health across the nine tests. Upside drivers would need to come from a change in the cash engine, which the source data does not show, and valuation is difficult to assess because P/E and EV/EBITDA are not available in source data. The market is pricing the stock at $0.86 with a market cap of $10.0M, near the bottom of its 52-week range of $0.81 to $4.19.
Phio Pharmaceuticals Corp. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The profile describes the company as a Health Care issuer with a market capitalization of $0.0B. Per the news wire, the company's pipeline focus includes a cancer approach designed to help immune cells fight tumors and a skin cancer program. Revenue reported in the SEC financials is $0.0M in each listed period, and the source data does not describe a product sales or monetization model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-9.2M | $-8.7M | N/A | $-8.0M | $21.0M | N/A |
| FY 2024 | $0.0M | $-7.4M | $-7.2M | N/A | $-7.1M | $5.4M | N/A |
| FY 2023 | $0.0M | $-10.8M | $-10.8M | N/A | $-10.7M | N/A | N/A |
Per the SEC financials, the company reported no revenue and operating losses in each period shown. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 1 out of 9, and a Debt/Equity of 0.5. Reported cash rose from $5.4M in FY 2024 to $21.0M in FY 2025, while debt is listed as N/A in every period.
Per the news wire, all six items relate to PHIO and carry a YELLOW light with a MARKET WIRE impact label. The headlines reference an upcoming presentation at The Global Markets Virtual Forum on October 8, 2026, a presentation at the National Investment Banking Association (NIBA) 153rd Conference, a planned Florida talk covering the skin cancer program, an estimates page from TradingView, and a Benzinga after-market mover listing. These are presentation and visibility events rather than reported financial results. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the profile classification in Health Care and Biotechnology: Pharmaceutical Preparations. A prospective investor should watch whether the company's cash position of $21.0M in FY 2025 is sufficient to fund continued operating losses of $-9.2M, but the source data does not provide a runway estimate.
Real-time company headlines, analyst actions, and sector developments for Phio Pharmaceuticals Corp. (PHIO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Phio Pharmaceuticals Corp. (PHIO) market action, institutional positioning, and fundamental catalysts.
Welcome to the PHIO (Phio Pharmaceuticals Corp.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PHIO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Phio Pharmaceuticals Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PHIO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.86 (52-wk range $0.81 - $4.19), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).